"Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results "a mixed quarter" and argued that the bar needs to come down before HIMS stock can work again."
"Hims & Hers posted revenue of $608.1 million against a consensus of $616.85 million, and reported diluted EPS of -$0.40 versus the Street's $0.03 expectation."
"Bank of America's core argument is straightforward: Street assumptions are too high in the near term, and consensus models need to recalibrate. The firm believes the bar must reset before Hims & Hers stock can find traction."
"The bigger story for Hims & Hers is the U.S. weight loss transition from compounded glucagon-like peptide-1 (GLP-1) drugs to branded alternatives. That shift drove $33.49 million in restructuring charges and weighed on U.S. revenue, which fell 8% year over year to $529.9 million."
Bank of America lowered its price objective for Hims & Hers to $30 from $32 while keeping a Neutral rating, citing a mixed quarter and the need for expectations to reset before the stock can perform. The Q1 2026 results missed on both revenue and earnings, with revenue of $608.1 million versus $616.85 million consensus and diluted EPS of -$0.40 versus $0.03 expected. Hims & Hers operates a multi-specialty telehealth platform with nearly 2.6 million subscribers, up 9% year over year. The company faces a U.S. weight loss transition from compounded GLP-1 drugs to branded alternatives, driving $33.49 million in restructuring charges and reducing U.S. revenue 8% year over year to $529.9 million.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]